Abbott Global Citizenship
2010 Highlights
Abbott Global Citizenship

Now more than ever, the sustainability of business and society are interconnected. At Abbott, we believe innovative, responsible and sustainable business plays an important role in building a healthy, thriving society. This idea lies at the heart of our global citizenship strategy.

We focus our global citizenship work on four key priorities: Innovating for the Future, Enhancing Access, Protecting Patients and Consumers, and Safeguarding the Environment. Within this framework, we apply our scientific expertise, business acumen, resources and talents to make a positive impact on the world around us. We strive to foster economic, environmental and social well-being – with our products, in the way we operate our company, and through our involvement with the communities where we live and work.

Abbott seeks to enhance the health, prosperity and quality of life in the communities we serve while rewarding our employees, partners and investors. In the process, we gain knowledge and experience that helps us create new products, bring efficiencies to our operations, and strengthen our relationships with patients and other stakeholders.

About this Report
This printed report summarizes Abbott’s 2010 global citizenship programs and documents progress toward our long-term goals. Visit www.abbott.com/citizenship to view our complete report, including detailed performance data.

About the Cover
Abbott works to expand health care access among India’s rural villages and urban poor. We sponsor a wide range of educational events and health fairs offering free diagnostics tests, screenings and advice for both acute and chronic diseases, as well as a mobile diagnosis and treatment van that serves India’s rural areas.
About Abbott
Abbott is a diverse, global health care company with scientific expertise and products that address the full range of health care needs – from disease prevention and diagnosis to treatment and cure. Our company discovers, develops, manufactures and markets leading pharmaceuticals, medical devices, diagnostics and nutrition products that are increasingly in demand in rapidly growing markets throughout the world. In 2010, despite a challenging global business environment, we achieved record sales of more than $35 billion, a 14.3 percent increase over 2009, and took decisive, strategic actions to better position our company for long-term growth.

Global Growth
Abbott’s success benefits patients, health care professionals, employees and shareholders around the world, enabling us to invest, innovate and introduce new products that improve health care. In 2010, 57 percent of our sales came from outside the United States, with strong performance in the emerging markets of Asia and Latin America.

Global Presence
Headquartered in north suburban Chicago, in the United States, Abbott serves a worldwide customer base with a staff of nearly 90,000 employees working in more than 130 countries.

2010 Net Sales
Dollars in billions
Total: $35
- Innovation-driven device businesses
  Vascular, molecular diagnostics, vision care
- Durable growth businesses
  Established pharmaceuticals, nutritionals, core diagnostics, diabetes care
- Proprietary pharmaceuticals
  U.S., international

2010 Summary of Worldwide Sales
- Innovation-driven device businesses
- Durable growth businesses
- Proprietary pharmaceuticals

International Sales Growth
Dollars in billions
2010: $20
2000: $4.7
Abbott’s international sales have more than quadrupled over the past 10 years as we continue expanding into new markets.
Miles D. White
Chairman and Chief Executive Officer
To Our Stakeholders:

We at Abbott are proud to present this summary of our 2010 Global Citizenship Report, published in full at www.abbott.com/citizenship. It provides an overview of our efforts to uphold the highest standards of corporate citizenship as we strive to advance global health and well-being, while rewarding our shareholders and employees.

2010 was another challenging year for business and the economy, worldwide. Nonetheless, Abbott delivered a 14.3 percent increase in sales, and took strategic actions that enhanced our leadership positions in both advanced technologies and emerging markets. Our expanding global presence allows us to serve more people than ever before. We are mindful of the responsibilities that come with that opportunity, and we take them very much to heart.

Abbott people around the world are committed to building a better, more sustainable enterprise. This requires us to be more thoughtful and creative in the way we conduct our business. And that’s a challenge we welcome, as it will make us a better company in multiple ways. Our long-held goal is to turn science into lasting contributions to health. And that commitment extends to every aspect of our business and our conduct.

Responsible global citizenship is central to the promise that Abbott makes to all the people we serve. We appreciate your interest in our determined efforts and continued progress.

Sincerely,

Miles D. White
Chairman and Chief Executive Officer
April 2011
Innovating for the Future

Enhancing Access

Protecting Patients and Consumers

Safeguarding the Environment
Redefining Responsibility

It’s what goes on in our laboratories and hallways, our offices and conference rooms. It’s what happens when we visit a hospital or health care clinic – whether in New York or Nairobi, Moscow or Mumbai, São Paulo or Shanghai.

It’s finding new solutions to old problems – and doing our part to make a difference.

It’s turning hope into innovative new medicines, medical devices, diagnostics and nutritional products. It’s forming creative partnerships to address emerging health care needs.

It’s turning our passion and dedication into ideas that improve people’s lives all over the world.

This is what we call “redefining responsibility.”

It’s what we do.
Redefining Responsibility

Innovating for the Future

Results

R&D Investment
Our investments in research and development enable us to foster new solutions for emerging health care challenges.

Collaborative Research
Abbott is engaged in a wide range of partnerships and alliances with peer companies, leading universities and research institutions to put great science to work. Our research collaborations are focused on important clinical areas such as cancer, Alzheimer’s disease, pain and the hepatitis C virus.

Science Education
More than 1 million students participate in Abbott-sponsored science education programs, inspiring and training the next generation of innovators.

<table>
<thead>
<tr>
<th>Year</th>
<th>R&amp;D Investment (in billions)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2005</td>
<td>$1.8</td>
</tr>
<tr>
<td>2006</td>
<td>$2.3</td>
</tr>
<tr>
<td>2007</td>
<td>$2.5</td>
</tr>
<tr>
<td>2008</td>
<td>$2.7</td>
</tr>
<tr>
<td>2009</td>
<td>$2.7</td>
</tr>
<tr>
<td>2010</td>
<td>$3.7</td>
</tr>
</tbody>
</table>

75 university partnerships

1 million+ students
For the past 120 years, Abbott has translated our passion for science, discovery and innovation into sustainable solutions to global health care challenges. With more than 350 clinical trials currently underway and more than 7,000 scientists working in our ten global research and development centers, we continue to pursue that same goal.

Our portfolio maintains a balance between higher-risk research projects aimed at breakthrough innovations and projects aimed at making meaningful, value-added improvements to existing products. At the same time, we constantly work to increase the efficiency of our R&D efforts.

We believe science is best practiced as a globally collaborative enterprise. That’s why we partner with a wide range of academic institutions, biotechnology firms, government agencies and health care companies whose skills, knowledge and perspectives complement ours and can help speed product development. For example, we are pioneering molecular testing technology that helps identify which cancer patients will benefit most from specific medicines. We also are partnering with several peer companies to screen tumors for the presence of specific genes and antigens.

Additionally, Abbott is working with leading nonprofit organizations to develop new medicines for neglected tropical diseases, as well as population-based approaches to help limit their spread.

1. Abbott is helping people in Ivory Coast understand how to prevent, detect and seek treatment for neglected tropical diseases like Buruli ulcer. Earlier diagnosis enables treatment to begin sooner — so that young patients can return to normal lives.

2. Abbott is among the world’s leading biologics research, development and manufacturing companies, and we have pioneering programs in small molecules. This balanced approach includes unique compounds for treating chronic kidney disease, women’s health, cancer, immune diseases, the hepatitis C virus and pain.

3. Marc Taub, Ph.D., a member of Abbott’s prestigious Volwiler Society of leading scientists, was inspired to work on new treatments for Type I diabetes after volunteering at a camp for children learning to manage the condition.

(L) Our integrated discovery project teams – composed of chemists, biologists, pharmacologists and related experts – work together across disciplines to advance scientific understanding. We have instituted numerous ways for scientific and technical employees to collaborate, including roundtable debates, collaborative reviews and a global online community.

See more online: www.abbott.com/citizenship/innovating
Redefining Responsibility

Enhancing Access

Results

Social Investing
Abbott and its nonprofit foundation, the Abbott Fund, support capacity-building partnerships, product donations and patient assistance programs around the world.

Enhancing Maternal and Child Health
We work with a wide range of partners to improve the health and status of women and children in Afghanistan, Cambodia, China and Vietnam. We also donate products to humanitarian relief agencies serving these vulnerable populations.

U.S. Patient Assistance
The Abbott Patient Assistance Foundation offers free medicines, nutrition and diabetes products to U.S. patients with financial difficulties. We participate in similar programs around the world.
Abbott brings high-quality medicines to patients and health care professionals in remote parts of India. These customers are served by a network of specially trained sales representatives — who, in many cases, grew up in those same villages.

1. We support the Fit for Work Coalition — a partnership of national health care systems, physician groups and other organizations dedicated to promoting physical activity and productivity among people with musculoskeletal disorders.

2. Partnering with Operation Smile, we have supported life-changing cleft lip and palate surgery for more than 1,600 children in India.

3. Employee volunteers from around the world are trained to mentor clinical laboratory professionals in Tanzania’s network of regional laboratories, supported by our nonprofit foundation, the Abbott Fund.

Expanding access to health care products, services, education and awareness is central to Abbott’s global citizenship commitment. We work to make essential, high-quality health care products affordable and accessible when and where they are needed.

Our 2010 acquisitions of Solvay Pharmaceuticals and Piramal’s domestic formulations business helped make Abbott a leader in offering affordable, high-quality branded generic medicines in many developing countries. We make Abbott products available at prices appropriate to each marketplace, enhancing access while preserving our ability to run our business sustainably. We also distribute free and reduced-price medicines through a variety of assistance programs, while donating pharmaceutical, medical and nutritional products to numerous humanitarian programs, medical missions and disaster relief efforts worldwide.

In addition, we recognize that chronic illnesses like diabetes, cancer, central nervous system disorders and heart disease are on the rise in the developing world, increasing the need for infrastructure and education. We partner with governments, non-governmental organizations and health care professionals to build health care system capacity and improve the quality, availability and frequency of training and education.
Protecting Patients and Consumers

Results

Improving Our Quality Systems
In 2007, we launched a rigorous training program to improve quality assurance practices at our operational sites. We continue enhancing our training and auditing functions around the world.

Broad Quality Training
This expanded training – encompassing 25 courses and available in 10 languages – enables employees to more effectively investigate potential quality issues and develop thorough corrective and preventive action plans.

Auditing Our Suppliers
Abbott routinely audits suppliers to ensure that they meet our expectations for both product quality and social responsibility standards such as ethics, management systems, employee health and safety and environmental performance. In 2010, we doubled our auditor training staff. We use a risk-based process to select suppliers for on-site audits, and we apply intensive screening in emerging markets where risks may be higher.

Rigorous quality assurance training

25 training courses in 10 languages
We also hold our 23,000 suppliers to our rigorous quality standards. During the past two years, we have completed formal quality performance scorecards for more than 80 percent of our critical suppliers. Additionally, we have conducted more than 1,000 on-site quality audits.

Abbott also conducts and supports a wide range of educational programs to assist patients, consumers and health care providers in timely, accurate disease prevention, diagnosis and treatment.

In 2010, our international pharmaceutical business unit launched a comprehensive initiative to strengthen our collaborations with patient groups around the world. Abbott’s dedicated staff work directly with patient associations at the local and regional levels to gain deeper insights into patient needs and challenges, improve disease management, advance quality of care, educate governments and raise public awareness.
Redefining Responsibility

Safeguarding the Environment

Results

Reducing Our Carbon Footprint
We’re committed to a 15 percent absolute reduction in our direct emissions and purchased electricity by 2015. By the end of 2010, we made significant progress toward that goal. Thus far, we have reduced CO₂ emissions by 13 percent.

Reducing Our Water Footprint
We’re committed to a 50 percent reduction in water use – adjusted for sales growth – by 2015. Since 2005, we’ve cut water use by nearly 47 percent. We’re using the World Business Council for Sustainable Development Global Water Tool to assess needs and develop conservation plans.

Reducing Waste
We’re committed to reducing our volume of waste and achieving five zero-waste-to-landfill manufacturing facilities by 2015. Our phased waste management strategy covers both our own manufacturing operations and, ultimately, those of our suppliers.
Abbott works diligently to reduce our global environmental impacts – from the sourcing of raw materials, to the manufacture and distribution of our products, to the use and disposal of our products by consumers and health care providers. Our environmental stewardship initiatives help protect the planet while improving efficiency, reducing costs and preserving our ability to do business in the future.

We view climate change as a serious environmental issue, and we are committed to helping address it. We measure and manage both direct and indirect carbon dioxide emissions. Our goal is to achieve an absolute 15 percent reduction in direct emissions and purchased electricity by 2015. Since 2005, we have reduced these emissions by 13 percent.

Abbott also is committed to efficient, sustainable water use and to improving access to clean water in the communities where we live and work. Twenty Abbott manufacturing sites are located in areas of water scarcity or water stress. In the last five years, we have reduced our total water intake by nearly 47 percent (adjusted for sales growth). Our goal is a 50 percent reduction by 2015.

Abbott’s product stewardship strategy is focused on ensuring quality, safety, and ease of use while minimizing the environmental impact of our products and packaging. We aggressively work to reduce the amount of materials used; remove chemicals of interest; recycle or reuse materials; and choose renewable packaging sources.
Our website includes analysis of our business and citizenship practices; updates on citizenship activities and programs; and in-depth feature stories on key issues and challenges.

Abbott has produced Global Citizenship Reports since 2000. While we once relied exclusively upon printed reports, our website has become our primary means for communicating Abbott’s citizenship initiatives.

The Strategic Priorities section demonstrates how we are embedding our four citizenship priorities – Innovating for the Future, Enhancing Access, Protecting Patients and Consumers and Safeguarding the Environment – into our daily operations.
The Key Metrics section provides interactive charts offering five-year trend data on our financial, social and environmental performance — including progress against our 2015 targets.

Our reporting focuses on material impacts and speaks to a range of audiences including customers, patients, employees, government and regulatory bodies, investors, special interest groups and non-governmental organizations.

We encourage you to visit www.abbott.com/citizenship to review our complete report, including detailed data on our financial, social and environmental performance.

The Reporting section of our website enables users to custom print selected sections of our website in PDF format.
Abbott is recognized by a variety of sustainability and socially responsible business indices and ratings.

- Abbott was included on the prestigious Dow Jones Sustainability World Index and North America Index for the sixth consecutive year in 2010 in recognition of continued global leadership in economic, environmental and social performance.

- Abbott ranked no. 24 on the Barron’s magazine 2010 ranking of the world’s 100 most respected companies and no. 21 on the Corporate Responsibility magazine 100 Best Corporate Citizens List. Abbott also was named Pharma Company of the Year and Management Team of the Year at the 2010 Scrip Awards.

- Abbott was named one of the top three “Best in Class” companies in our industry sector for financial, environmental and social performance by Storebrand Investments, a leading socially responsible investment (SRI) firm.

- Abbott has been included on the Ethibel Excellence Investment Register since 2005 in recognition of the company’s economic, social and environmental performance.

- Along with these global honors, Abbott has been recognized for our sustainability leadership in countries around the world, including Brazil, China, Denmark, Ireland, Italy, Korea, Mexico, Singapore, Tanzania and the United States.
As a company dedicated to innovation, Abbott seeks to inspire an interest in science among young people. Our scientists and technology experts visit elementary schools in Asia, Europe and North America to help children and their parents participate in fun, hands-on experiments conveying the wonder of discovery.

We also invite middle schoolers and their teachers to visit our laboratories – in China, Germany, Singapore, the United Kingdom and the United States. They meet top Abbott research scientists, tour our facilities and learn about the challenges and opportunities we encounter in developing new medicines and medical products.

Our science education programs have reached more than 1 million young people – helping to inspire the next generation of great scientists.